Financhill
Buy
56

ASH Quote, Financials, Valuation and Earnings

Last price:
$59.12
Seasonality move :
4.62%
Day range:
$58.56 - $59.30
52-week range:
$45.21 - $73.31
Dividend yield:
2.81%
P/E ratio:
21.24x
P/S ratio:
1.49x
P/B ratio:
1.41x
Volume:
469.1K
Avg. volume:
906.7K
1-year change:
-17.9%
Market cap:
$2.7B
Revenue:
$1.8B
EPS (TTM):
-$18.26

Analysts' Opinion

  • Consensus Rating
    Ashland, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $65.20, Ashland, Inc. has an estimated upside of 11.13% from its current price of $58.67.
  • Price Target Downside
    According to analysts, the lowest downside price target is $51.00 representing 100% downside risk from its current price of $58.67.

Fair Value

  • According to the consensus of 11 analysts, Ashland, Inc. has 11.13% upside to fair value with a price target of $65.20 per share.

ASH vs. S&P 500

  • Over the past 5 trading days, Ashland, Inc. has overperformed the S&P 500 by 0.55% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Ashland, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Ashland, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Ashland, Inc. reported revenues of $478M.

Earnings Growth

  • Ashland, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Ashland, Inc. reported earnings per share of $0.70.
Enterprise value:
3.9B
EV / Invested capital:
--
Price / LTM sales:
1.49x
EV / EBIT:
40.28x
EV / Revenue:
2.14x
PEG ratio (5yr expected):
7.83x
EV / Free cash flow:
108.54x
Price / Operating cash flow:
75.78x
Enterprise value / EBITDA:
10.18x
Gross Profit (TTM):
$437M
Return On Assets:
-16.22%
Net Income Margin (TTM):
-45.04%
Return On Equity:
-34.8%
Return On Invested Capital:
-21.45%
Operating Margin:
12.76%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Income Statement
Revenue $2.2B $2.1B $1.8B $522M $478M
Gross Profit $518M $494M $437M $154M $143M
Operating Income $163M $112M $97M $47M $61M
EBITDA $463M $440M $384M $104M $112M
Diluted EPS $3.26 $3.52 -$18.26 $0.33 $0.70
Period Ending 2021-09-30 2022-09-30 2023-09-30 2024-09-30 2025-09-30
Balance Sheet
Current Assets $1.7B $1.8B $1.5B $1.2B $1.2B
Total Assets $6.6B $6.2B $5.9B $5.6B $4.6B
Current Liabilities $934M $553M $456M $490M $423M
Total Liabilities $3.9B $3B $2.8B $2.8B $2.7B
Total Equity $2.8B $3.2B $3.1B $2.9B $1.9B
Total Debt $1.7B $1.4B $1.4B $1.4B $1.5B
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Cash Flow Statement
Cash Flow Operations $294M $462M $134M $80M $40M
Cash From Investing -$160M -$102M -$43M -$10M -$16M
Cash From Financing -$371M -$479M -$179M -$169M -$18M
Free Cash Flow $124M $325M $36M $42M $6M
ASH
Sector
Market Cap
$2.7B
$22.5M
Price % of 52-Week High
80.03%
72.97%
Dividend Yield
2.81%
0%
Shareholder Yield
7.56%
-2.79%
1-Year Price Total Return
-17.9%
13.1%
Beta (5-Year)
0.426
0.601
Dividend yield:
2.81%
Annualized payout:
$1.64
Payout ratio:
59.66%
Growth streak:
16 years

Technicals

8-day SMA
Sell
Level $59.32
200-day SMA
Buy
Level $52.37
Bollinger Bands (100)
Buy
Level 48.86 - 56.74
Chaikin Money Flow
Buy
Level 323.7M
20-day SMA
Sell
Level $59.01
Relative Strength Index (RSI14)
Buy
Level 56.99
ADX Line
Buy
Level 34.82
Williams %R
Neutral
Level -78.4777
50-day SMA
Buy
Level $53.86
MACD (12, 26)
Buy
Level 1.56
25-day Aroon Oscillator
Buy
Level 44
On Balance Volume
Neutral
Level 331.2M

Financial Scores

Hold
Altman Z-Score (Annual)
Level (1.8554)
Sell
CA Score (Annual)
Level (-0.3992)
Buy
Beneish M-Score (Annual)
Level (-3.5821)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.4596)
Buy
Piotroski F Score (Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (5)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Ashland, Inc. is an additives and specialty ingredients company, which engages in the provision of architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care, and pharmaceutical products. It operates through the following segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. The Life Sciences segment is involved in pharmaceuticals, nutrition, nutraceuticals, agricultural chemicals, diagnostic films, and fine chemicals. The Personal Care segment consists of biofunctionals, microbial protectants, skin care, sun care, oral care, hair care, and household solutions. The Specialty Additives segment focuses on rheology and performance-enhancing additives serving the architectural coatings, construction, energy, automotive, and various industrial markets. The Intermediates segment refers to production of 1,4 butanediol and related derivatives, including n-methylpyrrolidone. The company was founded in 1924 and is headquartered in Wilmington, DE.

Stock Forecast FAQ

In the current month, ASH has received 7 Buy ratings 4 Hold ratings, and 0 Sell ratings. The ASH average analyst price target in the past 3 months is $65.20.

  • Where Will Ashland, Inc. Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Ashland, Inc. share price will rise to $65.20 per share over the next 12 months.

  • What Do Analysts Say About Ashland, Inc.?

    Analysts are divided on their view about Ashland, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ashland, Inc. is a Sell and believe this share price will drop from its current level to $51.00.

  • What Is Ashland, Inc.'s Price Target?

    The price target for Ashland, Inc. over the next 1-year time period is forecast to be $65.20 according to 11 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.

  • Is ASH A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Ashland, Inc. is a Buy. 7 of 11 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of ASH?

    You can purchase shares of Ashland, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ashland, Inc. shares.

  • What Is The Ashland, Inc. Share Price Today?

    Ashland, Inc. was last trading at $59.12 per share. This represents the most recent stock quote for Ashland, Inc.. Yesterday, Ashland, Inc. closed at $58.67 per share.

  • How To Buy Ashland, Inc. Stock Online?

    In order to purchase Ashland, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did Stan Druckenmiller Sell Broadcom Stock?
Why Did Stan Druckenmiller Sell Broadcom Stock?

In Q3, legendary macro investor Stan Druckenmiller sold his entire…

Why Is CoreWeave Stock Down So Much?
Why Is CoreWeave Stock Down So Much?

AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…

Why Did Stan Druckenmiller Buy MercadoLibre Stock?
Why Did Stan Druckenmiller Buy MercadoLibre Stock?

In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…

Stock Ideas

Buy
55
Is NVDA Stock a Buy?

Market Cap: $4.5T
P/E Ratio: 63x

Buy
53
Is AAPL Stock a Buy?

Market Cap: $4T
P/E Ratio: 36x

Buy
61
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 39x

Alerts

Sell
30
CORT alert for Jan 2

Corcept Therapeutics, Inc. [CORT] is up 5.11% over the past day.

Buy
75
AXSM alert for Jan 2

Axsome Therapeutics, Inc. [AXSM] is down 3.83% over the past day.

Sell
50
NUTX alert for Jan 2

Nutex Health, Inc. [NUTX] is down 9.63% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock